Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1/2 Recruiting 30 enrolled Imunon Breakthrough Cancer Research · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

Timeline

Start: 2023-02-10
Primary completion: 2027-06-30
Completion: 2028-08-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMNN-001	Other / unclassified	80 mg/m2	Other
Background	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Background	Carboplatin	Small molecule	5 unknown	Intravenous
Background	Carboplatin	Small molecule	6 unknown	Intravenous
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Summary

Timeline

Drugs

Indications